Sanara MedTech Inc. (SMTI) intrinsic value & 10-year financials
Sanara MedTech Inc. (SMTI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 38.5% a year to $103.1M, with an average return on invested capital of -123.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $33.16
- Market cap
- $285.9M
- Revenue (FY2025)
- $103.1M
- Revenue growth (10-yr CAGR)
- 38.5%
- ROIC (10-yr avg)
- -123.4%
- Free cash flow (FY2025)
- $2.2M
SMTI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $103.1M | -$37.6M | -$4.36 | $2.2M | 7.1% | -81.1% |
| FY2024 | $86.7M | -$9.7M | -$1.14 | -$229.6K | -7.7% | -12.5% |
| FY2023 | $65.0M | -$4.3M | -$0.52 | -$3.5M | -6.5% | -10.2% |
| FY2022 | $45.8M | -$7.9M | -$1.00 | -$5.7M | -26.7% | -30.9% |
| FY2021 | $24.1M | -$8.0M | — | -$5.0M | -30.6% | -87.6% |
| FY2020 | $15.6M | -$4.4M | -$0.76 | -$4.6M | -32.3% | -154.1% |
| FY2019 | $11.8M | -$2.8M | -$1.32 | -$2.4M | -23.3% | -634.5% |
| FY2018 | $5.8M | -$600.6K | $0.00 | $268.7K | -8.6% | -132.0% |
| FY2017 | $6.3M | $331.3K | $0.00 | -$183.8K | 1.9% | — |
| FY2016 | $5.5M | -$415.7K | -$0.01 | $406.2K | -4.9% | 32.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Sanara MedTech Inc. is a consistent compounder, expanding top-line revenue at 38.5% annually over the past decade.
Sanara MedTech Inc. has historically struggled to out-earn its cost of capital, averaging just -36.6% ROIC.
Over the decade, Sanara MedTech Inc. shows that management has aggressively returned capital to shareholders by retiring 96.0% of outstanding shares, and that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Sanara MedTech Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-144.82 per share.